Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignant Skin Neoplasm”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00911443
What this trial is testing

Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma

Who this might be right for
Malignant Melanoma
sigma-tau i.f.r. S.p.A. 488
Testing effectiveness (Phase 2)Study completedNCT00104897
What this trial is testing

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma

Who this might be right for
Melanoma (Skin)
Cancer Research UK 25
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Testing effectiveness (Phase 2)UnknownNCT06006390
What this trial is testing

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Who this might be right for
Gastric CancerColon CancerRectal Cancer+4 more
Chongqing Precision Biotech Co., Ltd 60
Very early researchEnrolling By InvitationNCT07023848
What this trial is testing

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

Who this might be right for
Breast CancerGastric Cancer (GC)Urothelial Carcinoma (UC)
Affiliated Hospital of Jiangnan University 10
Early research (Phase 1)Study completedNCT03485547
What this trial is testing

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 5
Early research (Phase 1)Ended earlyNCT06799533
What this trial is testing

Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

Who this might be right for
Malignant MelanomaMelanomaMetastatic Melanoma+1 more
Pfizer 11
Testing effectiveness (Phase 2)Study completedNCT02076633
What this trial is testing

Intratumoral Administration of L19IL2/L19TNF

Who this might be right for
Malignant Melanoma, Skin
Philogen S.p.A. 21
Not applicableUnknownNCT04158544
What this trial is testing

Immune Monitoring in Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
University of Regensburg 100
Large-scale testing (Phase 3)Looking for participantsNCT05727904
What this trial is testing

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Who this might be right for
Metastatic MelanomaUnresectable MelanomaMelanoma
Iovance Biotherapeutics, Inc. 670
Testing effectiveness (Phase 2)Study completedNCT00003989
What this trial is testing

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Who this might be right for
Lung CancerMelanoma (Skin)
European Organisation for Research and Treatment of Cancer - EORTC 50
Testing effectiveness (Phase 2)Study completedNCT00383292
What this trial is testing

Tasisulam in Treating Participants With Malignant Melanoma

Who this might be right for
Metastatic Melanoma
Eli Lilly and Company 130
Not applicableStudy completedNCT00370136
What this trial is testing

Sentinel Node With Ultrasound Contrast in Melanoma

Who this might be right for
Malignant Melanoma
Rigshospitalet, Denmark 20
Testing effectiveness (Phase 2)Study completedNCT01618136
What this trial is testing

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Who this might be right for
Malignant Solid TumourOvarian CancerTriple Negative Breast Cancer+2 more
Eisai Limited 41
Early research (Phase 1)Study completedNCT01137006
What this trial is testing

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

Who this might be right for
Malignant Melanoma
Eli Lilly and Company 27
Early research (Phase 1)Ended earlyNCT00088647
What this trial is testing

Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Who this might be right for
Neoplasms
Wyeth is now a wholly owned subsidiary of Pfizer
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Not applicableStudy completedNCT00974610
What this trial is testing

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

Who this might be right for
Breast CancerColorectal CancerLung Cancer+2 more
Cancer Trials Ireland 803
Not applicableStudy completedNCT05126173
What this trial is testing

DERM US and EU Validation Study

Who this might be right for
Malignant Skin Melanoma T0Basal Cell CarcinomaSquamous Cell Carcinoma
Skin Analytics Limited 1,111
Early research (Phase 1)UnknownNCT05928962
What this trial is testing

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Who this might be right for
Malignant Melanomas
Fujian Cancer Hospital 10
Next Page